IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies

Several studies have identified mutations in the MYD88L265P gene as a key driver mutation in several B-cell lymphomas. B-cell lymphomas that harbor the MYD88L265P mutation form a complex with phosphorylated Bruton’s tyrosine kinase (BTK) and are responsive to BTK inhibition. However, BTK inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales: Parrondo, Ricardo D., Iqbal, Madiha, Von Roemeling, Reinhard, Von Roemeling, Christina, Tun, Han W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637517/
https://www.ncbi.nlm.nih.gov/pubmed/37954584
http://dx.doi.org/10.3389/fimmu.2023.1239082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637517/
https://www.ncbi.nlm.nih.gov/pubmed/37954584
http://dx.doi.org/10.3389/fimmu.2023.1239082

Ejemplares similares